PRCT Stock Forecast & Price Target

PROCEPT BioRobotics has demonstrated consistent growth in utilization, with handpiece usage per system increasing at an average rate of approximately 6.1% per quarter over the last six quarters, indicating a strengthening demand for its surgical robotics solutions. The company has also strategically committed to curbing the increase in operating expenses to half the rate of top-line growth, which is viewed positively by the market and suggests an approach towards improved profitability. Furthermore, expectations for accelerated handpiece utilization growth in FY26 signal potential for enhanced operational performance as the company continues to gain traction in the market following its recent product launches.

PROCEPT BioRobotics has experienced a significant decline in share value, dropping approximately 54% year-to-date, indicating disappointing financial performance despite the company's ability to meet its own guidance. Key risks to the company’s financial outlook include potential decreases in capital equipment demand, reduced handpiece usage by customers, heightened competitive pressures, and unfavorable changes in reimbursement policies for its Aquablation therapy. These factors collectively contribute to a negative perspective on the company’s future growth and market stability.